2.Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823-1833. doi:10.1056/NEJMoa1606774 3.Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of ...
PD-L1 positive cell line, H441, was positively stained for PD-L1 (Fig. 2B) while no PD-L1 expression was detected in PD-L1 negative cell line H1650 (Fig. 2C). The concentrations of all staining antibody were tested and optimized to avoid any cross-reaction. Isolation of CTCs in non-...
[4]Reck M, Rodríguez-Abreu D, Robinson AG, er al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2016, 375(19):1823-1833.[5]Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected ...
9. 872P Safety and efficacy of toripalimab combined with cetuximab in PD-L1 positive untreated recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase Ib/II study. Guo, Y. et al. Annals of Oncology, V...
[4]Reck M, Rodríguez-Abreu D, Robinson AG, er al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2016, 375(19):1823-1833.[5]Herbst RS, Giaccone G, de Marinis F, e...
免疫组织化学(immunohistochemistry,IHC,简称免疫组化)检测是评估肿瘤组织PD-L1表达状态的一种有效且最常用方法,广泛应用于包括非小细胞肺癌(non-small cell lung cancer, NSCLC)等在内的多种恶性肿瘤中,以识别或辅助预测可能从免疫治疗中获益的患者。 为更好地指导临床检测,中国抗癌协会肿瘤病理专业委员会肺癌学组...
期待斯鲁利单抗能在临床实践切实惠及更多食管癌患者,让他们活得更久、活得精彩。 参考文献: Yan Song, et al., First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nat Med. 2023 Feb;29(2):473-482....
Hayato Kawachi, et al 的多中心回顾性研究则发现,PD-L1 TPS ≥ 50% 的 aNSCLC 患者一线 Pembrolizumab 治疗,ECOG PS(≥ 2)和恶性胸腔积液是 PFS 缩短的独立预测因子。 研究者认为:伴恶性胸腔积液的 NSCLC 患者,可能并不适合一线单免治疗,即使其 PD-L1 TPS 高表达。
非鳞癌患者,PD-L1 高表达程度与生存时间提升显著相关,mOS 差异达 8.4 月。 鳞癌患者,PD-L1 表达情况与 OS 无统计学关联。 研究者结论:在一线 Pembrolizumab 治疗的非小细胞肺癌患者中,高 PD-L1 TPS 与非鳞 NSCLC 患者的 OS 获益相关,与鳞状 NSCLC 患者 OS 无关。
CPS:(肿瘤细胞&免疫细胞)阳性联合分数(Combined Positive Score); TC: 任何染色强度,肿瘤区域中肿瘤细胞染色的百分比(Tumor Cell); IC:肿瘤区域中的染色阳性免疫细胞所占面积的百分比(Immune Cell)。 四、检测前如何选择PD-L1检测抗体? PD-L1免疫组化抗体号多样化,且不同癌种的PD-L1蛋白评分指标及阈值不同,甚至...